Scott L. Burrows, CFO of Spyre Therapeutics ($SYRE), sold shares on the open market three times in the last year for a total of $401 thousand. His most recent sale occurred on March 3, 2026. These transactions rank 6,939th out of 11,678 insiders in our database, well below the average sale amount of $8.6 million across 6.37 transactions per insider. He made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 3, 2026 | Spyre Therapeutics, Inc. | $SYRE | Burrows Scott L | Chief Financial Officer | M | Stock Option (Right to Buy) | 2500 | $0.00 | 402,357.0000 | 78,540,164 | 0.62% | 0.00% |
| March 3, 2026 | Spyre Therapeutics, Inc. | $SYRE | Burrows Scott L | Chief Financial Officer | S | Common Stock | 200 | $41.66 | 97,994.0000 | 78,540,164 | 0.20% | 0.00% |
| March 3, 2026 | Spyre Therapeutics, Inc. | $SYRE | Burrows Scott L | Chief Financial Officer | S | Common Stock | 2300 | $40.56 | 98,194.0000 | 78,540,164 | 2.29% | 0.00% |
| March 3, 2026 | Spyre Therapeutics, Inc. | $SYRE | Burrows Scott L | Chief Financial Officer | M | Common Stock | 2500 | $14.50 | 100,494.0000 | 78,540,164 | 2.55% | 0.00% |
| Jan. 9, 2026 | Spyre Therapeutics, Inc. | $SYRE | Burrows Scott L | Chief Financial Officer | A | Stock Option (Right to Buy) | 140000 | $0.00 | 140,000.0000 | 77,592,130 | 9999.99% | 0.18% |
| Sept. 2, 2025 | Spyre Therapeutics, Inc. | $SYRE | Burrows Scott L | Chief Financial Officer | S | Common Stock | 18428 | $16.26 | 97,994.0000 | 60,275,561 | 15.83% | 0.03% |
| Jan. 15, 2025 | Spyre Therapeutics, Inc. | $SYRE | Burrows Scott L | Chief Financial Officer | A | Stock Option (Right to Buy) | 95500 | $0.00 | 95,500.0000 | 0 | 9999.99% | 0.00% |
| Sept. 3, 2024 | Spyre Therapeutics, Inc. | $SYRE | Burrows Scott L | Chief Financial Officer | S | Common Stock | 18531 | $28.17 | 116,422.0000 | 0 | 13.73% | 0.00% |
| Feb. 1, 2024 | Spyre Therapeutics, Inc. | $SYRE | Burrows Scott L | Chief Financial Officer | A | Stock Option (Right to Buy) | 70000 | $0.00 | 70,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 22, 2023 | Spyre Therapeutics, Inc. | $SYRE | Burrows Scott L | Chief Financial Officer | A | Common Stock | 134953 | $0.00 | 134,953.0000 | 0 | 9999.99% | 0.00% |
| Sept. 1, 2023 | Spyre Therapeutics, Inc. | $SYRE | Burrows Scott L | Chief Financial Officer | A | Stock Option (Right to Buy) | 10121441 | $0.00 | 10,121,441.0000 | 0 | 9999.99% | 0.00% |